Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. (Q37397710)
Jump to navigation
Jump to search
scientific article published on 15 September 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. |
scientific article published on 15 September 2015 |
Statements
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody (English)
Paul N Hopkins
Joep Defesche
Sigrid W Fouchier
Gérald Luc
Bertrand Cariou
Barbara Sjouke
Trond P Leren
Mariko Harada-Shiba
Hiroshi Mabuchi
Alain Carrié
Charles van Heyningen
Valérie Carreau
Michel Farnier
Yee P Teoh
Masa-Aki Kawashiri
Atsushi Nohara
Handrean Soran
A David Marais
Hayato Tada
Marianne Abifadel
Bernard Chanu
Shoji Katsuda
Ichiro Kishimoto
Hisashi Makino
Yoshihiro Miyamoto
Kunimasa Yagi
Masakazu Yamagishi
Yassine Zair
Scott Mellis
George D Yancopoulos
Neil Stahl
Johanna Mendoza
Yunling Du
Sara Hamon
Gary D Swergold
15 September 2015
1 reference
1 reference